Cencora, Inc.
No SEC Form 4 filings for $COR in the last 30 days.
See all $COR insider activity →Cencora reported Q3 2026 sales of $84.75B and net income of $763.52M, declared a $0.60 quarterly dividend, and amended credit facilities to expand liquidity and extend maturities. The article cites continued share repurchases totaling 7,950,265 shares for $2.00B and a multi-currency revolving credit facility expanded to $7.00B with maturities to 2031.
Cencora, Inc. (COR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001140859 0001140859 2026-08-13 2026-08-13 0001140859 us-gaap:CommonStockMember 2026-08-13 2026-08-13 0001140859 COR:Sec2.875SeniorNotesDue2028Member 2026-08-13 2026-08-13 0001140859 COR:Sec3.625SeniorNotesDue2032Member 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso421
Cencora (COR) is a pharma distributor with a $65B market cap. The stock lagged the S&P 500 over 1 year and fell in 2026. After Q3 2026 results on Aug. 5, revenue was $84.8B (below estimates) but adjusted EPS was $4.48 (above). Full-year EPS guidance is $17.75-$17.95. Morgan Stanley raised its COR target to $346.
Over the past 7 days, alphai's AI scored 6 news stories mentioning COR (Cencora, Inc.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 1 bearish.
Recent COR coverage spans earnings, market movers and corporate actions.
The article frames stronger earnings plus expanded committed liquidity as supportive of Cencora’s capital allocation and acquisition capacity, but flags margin and leverage risks.
Board change tied to a CFO appointment at another company, likely low immediate financial impact but relevant for governance and committee composition.
Earnings and full-year EPS guidance plus a raised Morgan Stanley price target create a near-term valuation and sentiment catalyst for COR.
Walgreens volume loss is the immediate driver of the selloff, partially offset by reaffirmed FY26 EPS guidance and a Wells Fargo price-target raise.
Walgreens volume moving outside Cencora’s operations is a near-term earnings mix risk, partially offset by guidance reaffirmation.
alphai scores every news story that mentions COR with an AI model for sentiment and relevance, and aggregates insider trades from Cencora, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cencora reported Q3 2026 sales of $84.75B and net income of $763.52M, declared a $0.60 quarterly dividend, and amended credit facilities to expand liquidity and extend maturities. The article cites continued share repurchases totaling 7,950,265 shares for $2.00B and a multi-currency revolving credit facility expanded to $7.00B with maturities to 2031.
6 min readCencora, Inc. (COR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001140859 0001140859 2026-08-13 2026-08-13 0001140859 us-gaap:CommonStockMember 2026-08-13 2026-08-13 0001140859 COR:Sec2.875SeniorNotesDue2028Member 2026-08-13 2026-08-13 0001140859 COR:Sec3.625SeniorNotesDue2032Member 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso421
2 min readCencora (COR) is a pharma distributor with a $65B market cap. The stock lagged the S&P 500 over 1 year and fell in 2026. After Q3 2026 results on Aug. 5, revenue was $84.8B (below estimates) but adjusted EPS was $4.48 (above). Full-year EPS guidance is $17.75-$17.95. Morgan Stanley raised its COR target to $346.
4 min readCencora (COR) shares fell 4.2% after the company said some Walgreens volume handled outside its prime vendor agreement began shifting to rival distributors as of July 1, 2026. Cencora said its core prime agreement remains intact and reaffirmed FY2026 adjusted diluted EPS guidance of $17.75 to $17.95. Wells Fargo raised its COR price target to $395. CFO James Cleary plans to sell about 20,000 shares.
4 min readCencora said it is reaffirming its full-year fiscal 2026 adjusted diluted EPS guidance of $17.75 to $17.95, unchanged from prior outlook, according to the company. Cencora also said that from July 1 some Walgreens volumes moved outside its operations, though its prime vendor agreement remains largely unchanged. Shares fell about 4.8% after the update.
4 min readCencora (COR) reported Q3 FY2026 revenue of $84.8B, up 5.1% year over year, and adjusted diluted EPS of $4.48, up 12.0%. Adjusted EPS guidance for FY2026 was raised to $17.75 to $17.95. Management cited OneOncology integration and $2.3B GLP-1 sales growth, plus $2.4B U.S. price headwinds. The company completed $1B share repurchases and repaid $800M debt.
8 min readCencora (COR) reported Q3 2026 sales of $84.75B and net income of $763.5M, and amended credit and receivables facilities, expanding revolving capacity to $7.0B. The company raised its fiscal 2026 adjusted EPS outlook, completed a $2.0B buyback tranche, and declared a $0.60 quarterly dividend. It flagged a possible earnings headwind tied to an MWI Animal Health-Covetrus merger.
4 min readCencora (NYSE:COR) reported Q3 results on its earnings call. U.S. Healthcare Solutions operating income rose 16% to $966 million, and International revenue grew 6% to $7.7 billion with operating income up 21% to $166 million. The company expects fiscal 2026 consolidated adjusted operating income growth of 13% to 14%, and said OneOncology integration is modestly ahead of initial expectations.
6 min readCencora reported Q3 2026 results driven by specialty pharmaceutical strength in health systems and physician practices, with its MSO platforms (including OneOncology and RCA) ahead of expectations. Adjusted EPS guidance for fiscal 2026 was raised to $17.75 to $17.95. The company completed $1 billion of share repurchases, expects U.S. Healthcare Solutions revenue in the lower half of 4% to 6% growth, and cited a $0.35 EPS headwind from the pending MWI Animal Health merger.
7 min readCencora (COR) reported Q3 sales of $84.754B, up 5.1% year over year and above the $84.315B consensus, driven by demand across its distribution networks. Gross profit rose 24.1% to $3.6B and operating income rose 29.1% to $1.1B. It raised FY2026 adjusted EPS guidance to $17.75-$17.95 and affirmed sales guidance. GLP-1 mix weighed on margins.
6 min read
